Computer simulations using GastroPlus™ to justify a biowaiver for etoricoxib solid oral drug products

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 72, Issue 1, 2009, Pages 91-98

  Okumu, Arthur ^a   DiMaso, Marie ^b   Löbenberg, Raimar ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

Author keywords

BCS; Bioequivalence; Etoricoxib; In silico; IVIVC; Permeability

Indexed keywords

ETORICOXIB;

ARTICLE; CELL STRAIN CACO 2; COMPUTER SIMULATION; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CULTURE TECHNIQUE; DRUG ABSORPTION; DRUG PENETRATION; DRUG SOLUBILITY; DRUG STRUCTURE; HUMAN; HUMAN CELL; INTESTINE FLUID; PH; STOMACH JUICE;

BUFFERS; CACO-2 CELLS; CHEMISTRY, PHARMACEUTICAL; COMPUTER SIMULATION; DOSAGE FORMS; DRUG DELIVERY SYSTEMS; HUMANS; HYDROGEN-ION CONCENTRATION; MODELS, CHEMICAL; PERMEABILITY; PHARMACEUTICAL PREPARATIONS; PYRIDINES; SOLUBILITY; SULFONES; THERAPEUTIC EQUIVALENCY; X-RAY DIFFRACTION;

EID: 62949224800     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2008.10.019     Document Type: Article

References (32)

1. Riendeau D., Percival M.D., Brideau C., Charleson S., Dube D., Ethier D., Falgueyret J.P., Friesen R.W., Gordon R., Greig G., Guay J., Mancini J., Ouellet M., Wong E., Xu L., Boyce S., Visco D., Girard Y., Prasit P., Zamboni R., Rodger I.W., Gresser M., Ford-Hutchinson A.W., Young R.N., and Chan C.C. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J. Pharmacol. Exp. Ther. 296 2 (2001) 558-566
2. Cochrane D.J., Jarvis B., and Keating G.M. Etoricoxib. Drugs 62 18 (2002) 2637-2651 discussion 2652-2633
3. Agrawal N.G., Porras A.G., Matthews C.Z., Rose M.J., Woolf E.J., Musser B.J., Dynder A.L., Mazina K.E., Lasseter K.C., Hunt T.L., Schwartz J.I., McCrea J.B., and Gottesdiener K.M. Single- and multiple-dose pharmacokinetics of etoricoxib, a selective inhibitor of cyclooxygenase-2, in man. J. Clin. Pharmacol. 43 3 (2003) 268-276
4. Dressman J.B., Amidon G.L., Reppas C., and Shah V.P. Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm. Res. 15 1 (1998) 11-22
5. Siewert M., Dressman J., Brown C.K., and Shah V.P. FIP/AAPS guidelines to dissolution/in vitro release testing of novel/special dosage forms. AAPS PharmSciTech 4 1 (2003) E7
6. Dressman J.B., Amidon G.L., and Fleisher D. Absorption potential: estimating the fraction absorbed for orally administered compounds. J. Pharm. Sci. 74 5 (1985) 588-589
7. Yu L.X., Lipka E., Crison J.R., and Amidon G.L. Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption. Adv. Drug Deliv. Rev. 19 3 (1996) 359-376
8. Charman W.N., Porter C.J., Mithani S., and Dressman J.B. Physiochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH. J. Pharm. Sci. 86 3 (1997) 269-282
9. Horter D., and Dressman J.B. Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. Adv. Drug Deliv. Rev. 46 1-3 (2001) 75-87
10. Galia E., Nicolaides E., Horter D., Lobenberg R., Reppas C., and Dressman J.B. Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. Pharm. Res. 15 5 (1998) 698-705
11. FDA, Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a Biopharmaceutics Classification System, 2002.
12. Potthast H., Dressman J.B., Junginger H.E., Midha K.K., Oeser H., Shah V.P., Vogelpoel H., and Barends D.M. Biowaiver monographs for immediate release solid oral dosage forms: ibuprofen. J. Pharm. Sci. 94 10 (2005) 2121-2131
13. Yu L.X., Amidon G.L., Polli J.E., Zhao H., Mehta M.U., Conner D.P., Shah V.P., Lesko L.J., Chen M.L., Lee V.H., and Hussain A.S. Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharm. Res. 19 7 (2002) 921-925
14. Blume H.H., and Schug B.S. The biopharmaceutics classification system (BCS): class III drugs - better candidates for BA/BE waiver?. Eur. J. Pharm. Sci. 9 2 (1999) 117-121
15. Yazdanian M., Briggs K., Jankovsky C., and Hawi A. The "high solubility" definition of the current FDA guidance on biopharmaceutical classification system may be too strict for acidic drugs. Pharm. Res. 21 2 (2004) 293-299
16. Tubic-Grozdanis M., Bolger M.B., and Langguth P. Application of gastrointestinal simulation for extensions for biowaivers of highly permeable compounds. AAPS J. 10 1 (2008) 213-226
17. Kostewicz E.S., Wunderlich M., Brauns U., Becker R., Bock T., and Dressman J.B. Predicting the precipitation of poorly soluble weak bases upon entry in the small intestine. J. Pharm. Pharmacol. 56 1 (2004) 43-51
18. Marques M. Dissolution Media Simulating fasted and Fed States (2004), Dissolution Technologies
19. Wei H., and Lobenberg R. Biorelevant dissolution media as a predictive tool for glyburide a class II drug. Eur. J. Pharm. Sci. 29 1 (2006) 45-52
20. FDA, Guidance for industry: extended release oral dosage forms: development, evaluation, and application of in vitro/in vivo correlations, US Department of Health, Food and Drug Administration, Center for Drug Evaluation and Research, 1997.
21. Dalton C.R., Clas S.D., Singh J., Khougaz K., and Bilbeisi R. Investigating the hydrate conversion propensity of different etoricoxib lots. J. Pharm. Sci. 95 1 (2006) 56-69
22. Yu L.X., Carlin A.S., Amidon G.L., and Hussain A.S. Feasibility studies of utilizing disk intrinsic dissolution rate to classify drugs. Int. J. Pharm. 270 1-2 (2004) 221-227
23. Meyer J.H., Elashoff J., Porter-Fink V., Dressman J., and Amidon G.L. Human postprandial gastric emptying of 1-3-millimeter spheres. Gastroenterology 94 6 (1988) 1315-1325
24. Theodorakis M.C., Digenis G.A., Beihn R.M., Shambhu M.B., and DeLand F.H. Rate and pattern of gastric emptying in humans using 99mTc-labeled triethylenetetraamine-polystyrene resin. J. Pharm. Sci. 69 5 (1980) 568-571
25. Naylor L.J., Bakatselou V., and Dressman J.B. Comparison of the mechanism of dissolution of hydrocortisone in simple and mixed micelle systems. Pharm. Res. 10 6 (1993) 865-870
26. Crison J.R., Shah V.P., Skelly J.P., and Amidon G.L. Drug dissolution into micellar solutions: development of a convective diffusion model and comparison to the film equilibrium model with application to surfactant-facilitated dissolution of carbamazepine. J. Pharm. Sci. 85 9 (1996) 1005-1011
27. United States Pharmacopeia - National Formulary, United state pharmacopeial convention, 2006.
28. Von Weimarn P.P. The precipitation laws. Chem. Rev. 2 2 (1925) 217-242
29. Amidon G.L., Lennernas H., Shah V.P., and Crison J.R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12 3 (1995) 413-420
30. Polli J.E., Yu L.X., Cook J.A., Amidon G.L., Borchardt R.T., Burnside B.A., Burton P.S., Chen M.L., Conner D.P., Faustino P.J., Hawi A.A., Hussain A.S., Joshi H.N., Kwei G., Lee V.H., Lesko L.J., Lipper R.A., Loper A.E., Nerurkar S.G., Polli J.W., Sanvordeker D.R., Taneja R., Uppoor R.S., Vattikonda C.S., Wilding I., and Zhang G. Summary workshop report: biopharmaceutics classification system - implementation challenges and extension opportunities. J. Pharm. Sci. 93 6 (2004) 1375-1381
31. FDA, Guidance for industry: immediate release solid oral dosage forms. Scale-up and post-approval changes: chemistry, manufacturing and controls, in vitro dissolution testing, and in vivo bioequivalence documentation (SUPAC-IR), US. Department of Health, Food and Drug Administration, Center for Drug Evaluation and Research, 1995.
32. WHO expert committee on specifications for pharmaceutical preparations. Fortieth report, World Health Organ Tech Rep Ser, 2006. pp. 1-461.